Skip to main content
Kent Academic Repository

Combined point of care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G Spike Variant

Mlcochova, Petra, Collier, Dami, Ritchie, Allyson, Assennato, Sonny M., Hosmillo, Myra, Goel, Neha, Meng, Bo, Chatterjee, Krishna, Mendoza, Vivien, Temperton, Nigel J., and others. (2020) Combined point of care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G Spike Variant. Cell Reports Medicine, . Article Number 100099. ISSN 2666-3791. (doi:10.1016/j.xcrm.2020.100099) (KAR id:82736)

Abstract

Rapid COVID-19 diagnosis in hospital is essential, though complicated by 30-50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant now dominates the pandemic and it is unclear how serological tests designed to detect anti-Spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wild type or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95CI 57.8-92.9%) by rapid NAAT alone. Combined point of care antibody test and rapid NAAT is not impacted by D614G and results in very high sensitivity for COVID-19 diagnosis with very high specificity.

Item Type: Article
DOI/Identification number: 10.1016/j.xcrm.2020.100099
Subjects: Q Science > QR Microbiology > QR355 Virology
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User: Nigel Temperton
Date Deposited: 02 Sep 2020 15:35 UTC
Last Modified: 04 Mar 2024 16:25 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/82736 (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.